RenovoRx receives additional 180-day compliance period for minimum bid price
RenovoRx received notification from Nasdaq on July 1, 2026, that while the company has not regained compliance with the $1.00 minimum bid price requirement, it is eligible for an additional 180 calendar day period, or until December 28, 2026, to regain compliance. If the closing bid price does not reach at least $1.00 per share for a minimum of 10 consecutive business days by that date, Nasdaq will notify the company that its common stock will be delisted, though the company may appeal the determination.
Key facts
- Additional compliance period: until December 28, 2026
- Minimum bid price requirement: $1.00 per share
- Compliance condition: $1.00 or higher for 10 consecutive business days
- Initial deficiency notice received: December 31, 2025
- Initial 180-day compliance period deadline: June 30, 2026
Why it matters
RenovoRx has been granted a second cure period but faces delisting if it cannot sustain a $1.00 stock price for 10 consecutive business days by late December 2026, which would threaten the company's access to Nasdaq capital markets.
Share
Derived from 8-K filed 2026-07-02. Not investment advice. View the source filing on SEC.gov →